Category: Peptide Q&A
-
What is the quality and consistency of human clinical evidence supporting MOTS-c’s metabolic benefits, and how many randomized controlled trials exist?
What is the quality and consistency of human clinical evidence supporting MOTS-c’s metabolic benefits, and how many randomized controlled trials exist?
-
What role does MOTS-c play in activating AMPK and inhibiting mTOR signaling, and how does this influence longevity pathways?
What role does MOTS-c play in activating AMPK and inhibiting mTOR signaling, and how does this influence longevity pathways?
-
How do in vitro studies on MOTS-c compare with in vivo findings in terms of reproducibility and biological relevance?
How do in vitro studies on MOTS-c compare with in vivo findings in terms of reproducibility and biological relevance?
-
Does MOTS-c influence mitochondrial biogenesis through PGC-1α or other transcription factors, and what evidence supports this?
Does MOTS-c influence mitochondrial biogenesis through PGC-1α or other transcription factors, and what evidence supports this?
-
How does MOTS-c compare to other mitochondrial-targeted peptides like SS-31 or Z-10 in terms of metabolic and anti-aging effects?
How does MOTS-c compare to other mitochondrial-targeted peptides like SS-31 or Z-10 in terms of metabolic and anti-aging effects?
-
Can MOTS-c promote tissue repair in models of muscle atrophy or age-related sarcopenia, and what are the underlying cellular mechanisms?
Can MOTS-c promote tissue repair in models of muscle atrophy or age-related sarcopenia, and what are the underlying cellular mechanisms?
-
In what ways does MOTS-c differ from metformin or GLP-1 agonists in its mechanism of action and side effect profile?
In what ways does MOTS-c differ from metformin or GLP-1 agonists in its mechanism of action and side effect profile?
-
What are the current barriers to widespread clinical adoption of kisspeptin, including manufacturing and reimbursement issues?
What are the current barriers to widespread clinical adoption of kisspeptin, including manufacturing and reimbursement issues?